Steven Cohen's IONS Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.23 M shares of Ionis Pharmaceuticals, Inc. (IONS) worth $54.82 M, representing 0.06% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 29 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2026, adding 1.23 M shares. Largest reduction occurred in Q3 2021, reducing 757,600 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +1.23 M | New Buy | 1.23 M | $44.65 |
| Q3 2025 | -292,647 | Sold Out | 0 | $0.00 |
| Q2 2025 | +5,443 | Add 1.90% | 292,647 | $39.51 |
| Q1 2025 | +287,204 | New Buy | 287,204 | $30.17 |
| Q3 2024 | -137,210 | Sold Out | 0 | $0.00 |
| Q2 2024 | -149,392 | Reduce 52.13% | 137,210 | $47.66 |
| Q1 2024 | -682,198 | Reduce 70.42% | 286,602 | $43.35 |
| Q4 2023 | +827,300 | Add 584.66% | 968,800 | $50.59 |
| Q3 2023 | -62,900 | Reduce 30.77% | 141,500 | $45.36 |
| Q2 2023 | +108,515 | Add 113.17% | 204,400 | $41.03 |
| Q1 2023 | +95,885 | New Buy | 95,885 | $35.74 |
| Q3 2022 | -13,185 | Sold Out | 0 | $0.00 |
| Q2 2022 | +13,185 | New Buy | 13,185 | $37.01 |
| Q1 2022 | -53,981 | Sold Out | 0 | $0.00 |
| Q4 2021 | -165,319 | Reduce 75.38% | 53,981 | $30.44 |
| Q3 2021 | -757,600 | Reduce 77.55% | 219,300 | $33.54 |
| Q2 2021 | +976,900 | New Buy | 976,900 | $39.89 |
| Q1 2021 | -402,400 | Sold Out | 0 | $0.00 |
| Q4 2020 | +113,908 | Add 39.48% | 402,400 | $56.54 |
| Q3 2020 | +113,867 | Add 65.21% | 288,492 | $47.45 |
| Q2 2020 | +169,052 | Add 3033.41% | 174,625 | $58.96 |
| Q1 2020 | +5,573 | New Buy | 5,573 | $47.19 |
| Q4 2018 | -86,031 | Sold Out | 0 | $0.00 |
| Q3 2018 | +86,031 | New Buy | 86,031 | $51.57 |
| Q4 2017 | -25,000 | Sold Out | 0 | $0.00 |
| Q3 2017 | +25,000 | New Buy | 25,000 | $50.72 |
| Q2 2016 | -80,600 | Sold Out | 0 | $0.00 |
| Q1 2016 | -217,300 | Reduce 72.94% | 80,600 | $40.50 |
| Q4 2015 | +297,900 | New Buy | 297,900 | $61.93 |
Steven Cohen's Ionis Pharmaceuticals Investment FAQs
Steven Cohen first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2015, acquiring 297,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Ionis Pharmaceuticals, Inc. (IONS) for 29 quarters since Q4 2015.
Steven Cohen's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q3 2026, adding 1,227,788 shares worth $54.82 M.
According to the latest 13F filing for Q3 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,227,788 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $54.82 M.
As of the Q3 2026 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.06% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 1,227,788 shares, as reported at the end of Q3 2026.